• FirefoxUpgrade to the new Firefox »
  •  Dow Up1.69% Nasdaq Up2.12%

    Valeant Pharmaceuticals International, Inc. (VRX)

    -NYSE
    140.00 3.08(2.25%) Dec 17, 4:02PM EST
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
    Total Revenue 5,769,605   3,480,376   2,427,450  
    Cost of Revenue1,905,120  969,696  696,098  
    Gross Profit 3,864,485   2,510,680   1,731,352  
    Operating Expenses
    Research Development156,783  79,052  65,687  
    Selling General and Administrative1,510,347  810,166  568,061  
    Non Recurring704,880  612,892  239,831  
    Others1,901,977  928,885  557,814  
    Total Operating Expenses4,273,987  2,430,995  1,431,393  
    Operating Income or Loss (409,502) 79,685   299,959  
    Income from Continuing Operations
    Total Other Income/Expenses Net(60,634)7,683  16,567  
    Earnings Before Interest And Taxes(470,136)87,368  316,526  
    Interest Expense844,316  481,596  334,526  
    Income Before Tax(1,314,452)(394,228)(18,000)
    Income Tax Expense(450,783)(278,203)(177,559)
    Minority Interest(2,473) -   -  
    Net Income From Continuing Ops(931,156)(136,105)122,715  
    Non-recurring Events
    Discontinued Operations -   -   -  
    Extraordinary Items -   -   -  
    Effect Of Accounting Changes -   -   -  
    Other Items -   -   -  
    Net Income (866,142) (116,025) 159,559  
    Preferred Stock And Other Adjustments -   -   -  
    Net Income Applicable To Common Shares (866,142) (116,025) 159,559  

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.